AstraZeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India (DCGI) for FDC of Budesonide 320 g +Formoterol Fumarate Dihydrate 9 g inhalation powder.
FDC of Budesonide 320 g + Formoterol Fumarate Dihydrate 9 g inhalation powder (Symbicort Turbuhaler 320/9 g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting β-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
